Navin Pinto
机构: University of Colorado Anschutz Medical Campus
每年引用次数
引用次数
引用: 3,290
H-指数: 24
I10-指数 : 41
出版物: 132
Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival
Eric R. Gamazon , Navin Pinto , Anuar Konkashbaev , Hae Kyung Im
Journal of the National Cancer Institute 105 ( 4) 302 -309
34
2012
Towards Personalized Medicine in Pediatric Cancer: Genome-Wide Strategies to Investigate Cancer Risk and Response to Therapy
Navin Pinto , Kenan Onel
Pediatric Neoplasia 1 -19
2012
A pharmacodynamic study of sirolimus and metformin in patients with advanced solid tumors
Amikar Sehdev , Theodore Karrison , Yuanyuan Zha , Linda Janisch
Cancer Chemotherapy and Pharmacology 82 ( 2) 309 -317
8
2018
Predictors of differential response to induction therapy in high-risk neuroblastoma: A report from the Children's Oncology Group (COG).
Navin Pinto , Arlene Naranjo , Emily Hibbitts , Susan G. Kreissman
European Journal of Cancer 112 66 -79
13
2019
Promising Chimeric Antigen Receptors for Non-B-Cell Hematological Malignancies, Pediatric Solid Tumors, and Carcinomas
Jacob S. Appelbaum , Navin Pinto , Rimas J. Orentas
Elsevier 137 -163
1
2020
Extensive small bowel pneumatosis and ischemia during dinutuximab therapy for high-risk neuroblastoma.
Katherine Spencer , Erin Romberg , Navin Pinto
Pediatric Blood & Cancer 67 ( 4)
1
2020
Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence.
Navin Pinto , Jodi R. Mayfield , Gordana Raca , Mark A. Applebaum
Pediatric Blood & Cancer 63 ( 6) 1019 -1023
6
2016
Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients.
Elizabeth Sokol , Eryong Huang , Peter Pytel , Susan L Cohn
Pediatric Blood & Cancer 64 ( 3)
1
2017
Patterns of PD-1, PD-L1, and PD-L2 expression in pediatric solid tumors
Navin Pinto , Julie R. Park , Erin Murphy , Jennifer Yearley
Pediatric Blood & Cancer 64 ( 11) e26613
26
2017
Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial
Navin Pinto , Steven G. DuBois , Araz Marachelian , Scott J. Diede
Pediatric Blood & Cancer 65 ( 7)
16
2018
Late effects in high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell rescue
Mahmoud M. Elzembely , Ann E. Dahlberg , Navin Pinto , Kasey J. Leger
Pediatric Blood & Cancer 66 ( 1)
8
2019
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma.
Elizabeth A. Sokol , Roger Engelmann , Wenjun Kang , Navin Pinto
Pediatric Blood & Cancer 65 ( 12)
2018
Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy.
Navin Pinto , Susan M Ludeman , M Eileen Dolan
Pharmacogenomics 10 ( 12) 1897 -1903
61
2009
Establishing a translational genomics infrastructure in pediatric cancer: the GREAT KIDS experience
Navin Pinto , Samuel L Volchenboum , Andrew D Skol , Lindsay Rhodes
Personalized Medicine 12 ( 3) 221 -229
1
2015
Abstract A175: Phase 1 study of the EZH2 inhibitor, tazemetostat, in children with relapsed or refractory INI1-negative tumors including rhabdoid tumors, epithelioid sarcoma, chordoma, and synovial sarcoma
Susan Chi , Maryam Fouladi , Neerav Shukla , Franck Bourdeaut
Molecular Cancer Therapeutics 17
4
2018
IMMU-11. BRAINCHILD PIPELINE: LOCOREGIONAL IMMUNOTHERAPY WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS FOR RECURRENT/REFRACTORY CENTRAL NERVOUS SYSTEM TUMORS
Nicholas Vitanza , Juliane Gust , Sarah Leary , Navin Pinto
Neuro-oncology 20
2018
IMMU-03. UPDATES ON BRAINCHILD-01, -02, AND -03: PHASE 1 LOCOREGIONAL CAR T CELL TRIALS TARGETING HER2, EGFR, AND B7-H3 FOR CHILDREN WITH RECURRENT CNS TUMORS AND DIPG
Nicholas Vitanza , Juliane Gust , Ashley Wilson , Wenjun Huang
Neuro-oncology 22
2020
Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis
Nicholas A Vitanza , Adam J Johnson , Ashley L Wilson , Christopher Brown
Nature medicine 27 ( 9) 1544 -1552
77
2021
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: Phase 1 trial results
Kelly C Goldsmith , Julie R Park , Kimberly Kayser , Jemily Malvar
Nature medicine 29 ( 5) 1092 -1102
45
2023
Integrating Cell‐Based and Clinical Genome‐Wide Studies to Identify Genetic Variants Contributing to Treatment Failure in Neuroblastoma Patients
Navin Pinto , Eric R Gamazon , Nirav Antao , Jamie Myers
Clinical Pharmacology & Therapeutics 95 ( 6) 644 -652
4
2014